CD274 and rectal cancer: However, both ESCORT (Evaluation of Efficacy, Quality of Life and Cost Effectiveness of Short-course Radiotherapy Followed by Capecitabine Plus Oxaliplatin chemotheRapy and TME for High-risk Rectal Cancer)58 and ATTRACTION-3 (Nivolumab Versus Chemotherapy in Patients With Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy)59 trials showed that patients benefited from immunotherapy regardless of PD-L1 expression levels.